- Medicenna Therapeutics (MDNA) has appointed Dr. Kevin Moulder, a veteran in the immunology and oncology industries, as the company’s Chief Scientific Officer
- Dr. Moulder will be a key driver in the development of the company’s Superkine and BiSKITs platforms
- Medicenna is a clinical-stage immunotherapy company focused on the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer
- Medicenna Therapeutics Corp. (MDNA) is up 0.62 per cent and is trading at $4.85 per share
Medicenna Therapeutics (MDNA) has appointed Dr. Kevin Moulder as the company’s Chief Scientific Officer.
Dr. Moulder, a veteran in the immunology and oncology industries, has over 30 years of experience in drug discovery and development in the fields of protein design, antibody technology, immuno-oncology, inflammation and autoimmune disease.
Dr. Fahar Merchant, President and CEO of Medicenna, commented,
“We are thrilled to welcome Kevin to Medicenna as his scientific and technical expertise will be instrumental in the development of our novel Superkine and BiSKITs™ platforms and while helping to expand our clinical-stage pipeline.”
Dr. Moulder holds a first-class honours degree in biological sciences and a Ph.D. in Immunology from the University of London.
He commented,
“The opportunity to serve as Medicenna’s CSO is truly exciting. The company’s Superkine and BiSKITs™ platforms are powerful tools that have generated potentially first and best-in-class assets designed to overcome the limitations of currently available immunotherapies.”
Medicenna is a clinical-stage immunotherapy company focused on the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer.
Medicenna Therapeutics Corp. (MDNA) is up 0.62 per cent and is trading at $4.85 per share as of 11:02 am ET.